CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...
Zacks Investment Research on MSN
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
In the latest close session, Moderna (MRNA) was up +1.87% at $26.74. The stock outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing of 1.01%, while the tech-heavy Nasdaq ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
A medida que se aproximaba el comienzo de la temporada de la NBA esta semana, el entrenador Rick Carlisle y los Pacers de Indiana recibieron su informe anual ...
Cambridge-based Tender announced the launch of a new venture, Lasso Spin Tech, within the company. The company kicked off ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
New research shows Moderna and Pfizer’s mRNA vaccines may prime the immune system to attack cancer—even better than some ...
A judge has denied BioMed Realty’s motions to intervene in its bid to recover millions from a tenant over a breached ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback